section name header

Pronunciation

tel-mi-SAR-tan

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: angiotensin II receptor antagonists

Indications

REMS


Action

  • Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II at various receptor sites, including vascular smooth muscle and the adrenal glands.
Therapeutic effects:
  • Lowering of BP.
  • Reduction of risk of MI, stroke, or cardiovascular death.

Pharmacokinetics

Absorption: 42–58% absorbed following oral administration (bioavailability increased in patients with hepatic impairment).

Distribution: Crosses the placenta.

Protein Binding: 99.5%.

Metabolism/Excretion: Excreted mostly unchanged in feces via biliary excretion.

Half-Life: 24 hr.

Time/Action Profile

(antihypertensive effect)

ROUTEONSETPEAKDURATION
POwithin 3 hr*4 wk24 hr



*After single dose.

Chronic dosing.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension

EENT: sinusitis

F and E: hyperkalemia

GI: abdominal pain, diarrhea, dyspepsia

GU: renal impairment

MS: back pain, myalgia

Neuro: dizziness, fatigue, headache

Misc: ANGIOEDEMA

Interactions

Drug-drug:

Route/Dosage

Hypertension

Cardiovascular Risk Reduction

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Micardis